Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Dossier - 31/03/2014 Teaser_adrenomedullin_WikimediaImages_pixabay_g566109ad4_1920.jpg

    Peptides diverse molecules of life

    Peptides exist in all organisms, wherever there are cells. The range of their physiological functions is huge. Biologically active peptides can act as hormones, neurotransmitters, growth factors as well as toxins and antibiotics. This is what makes them highly interesting drug leads. They are used for the treatment of autoimmune diseases, cancer and other diseases. Peptides are gaining in importance as candidates for drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/peptides-diverse-molecules-of-life
  • Press release - 24/01/2023

    Genome Editing Procedures Optimised

    Heidelberg scientists succeed in boosting the efficiency of CRISPR/Cas9 and related methods and modifying initially inaccessible DNA sequences.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/verfahren-der-genom-editierung-optimiert
  • Press release - 25/06/2025

    Otto Hahn Medal for Jonas Wilhelm

    For his outstanding achievements in his doctorate at the interface between chemistry and biology, Jonas Wilhelm is awarded an Otto Hahn Medal 2025 by the Max Planck Society. He wrote his thesis in the department Chemical Biology of Kai Johnsson at the Max Planck Institute for Medical Research. In his doctorate, Jonas Wilhelm developed a molecular tool, a biosensor that records and permanently stores biological activities at the cellular level.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/otto-hahn-medal-jonas-wilhelm
  • Atriva Therapeutics - 21/10/2020 Kulturschalen mit blau angefärbten Zellen, zu denen das neue Coronavirus (SARS CoV-2) gegeben wurde. Die mit dem Wirkstoff ATR-002 von Atriva Therapeutics behandelten Zellen (rechte Reihen) zeigen keine weißen Löcher im Zellrasen und somit keine Zellzerstörung.

    COVID-19 pioneer drug in Phase II clinical trial - with double the power

    The effective treatment of people with severe COVID-19 is a major goal during the corona pandemic. ATR-002, an oral small molecule that targets RNA viruses such as influenza virus and SARS-CoV-2, has a dual effect: it impairs viral propagation and also has an immunomodulatory effect. And what’s more, due to its unique cellular mechanism of action, the efficacy of Atrivia Therapeutics’ drug candidate is not reduced by virus mutations and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/covid-19-pioneer-drug-phase-ii-clinical-trial-double-power
  • Article - 30/09/2019 Massenspektrometrie.jpg

    Do gut bacteria have something to do with autism?

    Autistic people have different gut microorganisms than non-autistic people. Researchers believe that a disturbed intestinal flora may play a role in developmental disorders of the brain such as autism. The emerging new field of metaproteomics could shed light onto the matter. A team led by Prof. Dr. Boris Macek from Tübingen has investigated the bacterial protein pool in the faeces of mice that display autistic behaviour.

    https://www.gesundheitsindustrie-bw.de/en/article/news/do-gut-bacteria-have-something-to-do-with-autism
  • Press release - 04/07/2024

    Antibody can improve immune cell therapy against leukemia

    Scientists from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD) have shown that the combination of therapeutic immune cells, known as CAR T cells, and a bispecific antibody could improve the treatment of leukaemia. In the culture dish and in mice, they tested CAR-T cells directed against the B-cell marker CD19 in combination with bispecific antibodies that bind to the B-cell-specific protein CD20.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/antibody-can-improve-immune-cell-therapy-against-leukemia
  • Press release - 25/05/2021

    How “paralyzed” immune cells can be reactivated against brain tumors

    Brain tumor cells with a certain common mutation reprogram invading immune cells. This leads to the paralysis of the body's immune defense against the tumor in the brain. Researchers from Heidelberg, Mannheim, and Freiburg discovered this mechanism and at the same time identified a way of reactivating the paralyzed immune system to fight the tumor.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-paralyzed-immune-cells-can-be-reactivated-against-brain-tumors
  • Press release - 12/05/2022

    New hope for broad spectrum viral entry inhibitors – Negatively charged polymer proves effective against a wide range of viruses

    While broad-spectrum antibiotics can offer protection against a wide variety of bacteria, there are currently no analogous clinically available broad-spectrum antiviral agents that can act on several different viruses. An international research team has now shown that polystyrene sulfonate (PSS), a negatively charged polymer, has the potential to be used in the prevention of viral infections – not only in the fight against the SARS-CoV-2 and cold…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-hope-broad-spectrum-viral-entry-inhibitors-negatively-charged-polymer-proves-effective-against-wide-range-viruses
  • Press release - 18/01/2024

    Indicator for liver health status identified

    A high-fat, high-sugar diet damages the liver in the long term. Scientists at the German Cancer Research Center (DKFZ) have now identified a characteristic change in the molecular signaling pathways of liver cells in mice that were exposed to such a diet for weeks. It fuels the division activity of hepatocytes and correlates with the risk of patients suffering liver failure after liver surgery.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/indicator-liver-health-status-identified
  • DNA nanotechnology - 25/08/2023 Graphic representation of the transport mechanism induced by digestion with RNase H of a vesicle shown in red along gray colored filaments.

    Artificial cytoskeleton made of DNA for synthetic cells

    The physicists Prof. Dr. Kerstin Göpfrich and Prof. Dr. Laura Na Liu want to understand life from the bottom up. They intend to do this by constructing an artificial cell. However, rather than natural protein building blocks, they are using 3D-DNA structures as construction material. The first step involved creating an artificial cell skeleton that dynamically assembles and disassembles like the biological model and can transport vesicles.

    https://www.gesundheitsindustrie-bw.de/en/article/news/artificial-cytoskeleton-made-dna-synthetic-cells
  • Press release - 14/03/2024

    Next milestone in the treatment of liver tumors and acute and chronic liver diseases

    The results of a Tuebingen-led study raise hope that a newly developed drug could herald a new era in oncological liver surgery and transplantation. The drug could even have the potential to significantly improve the treatment of acute and chronic liver diseases. The drug candidate "HRX-215" is a so-called MKK4 inhibitor, i.e. the drug inhibits the MKK4 protein found in liver cells and thus leads to an increase in the regeneration of…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/next-milestone-treatment-liver-tumors-and-acute-and-chronic-liver-diseases
  • Dossier - 02/12/2013 AI generated symbolic image of an RNA strand.

    RNA interference confidence is returning

    The 15-year history of RNA interference is not short on dramatic effects. It begins with the unexpected discovery and publication of the process of post-transcriptional gene silencing in 1998 for which Andrew Fire and Craig Mello were awarded the Nobel Prize in Physiology or Medicine just eight years after their discovery. In 2001 Thomas Tuschl succeeded in switching off genes in human cells with small synthetic pieces of RNA siRNA.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/rna-interference-confidence-is-returning
  • Press release - 19/10/2022

    Molecular structure of one of the most important receptors in the immune system unraveled

    Researchers from Freiburg and Harvard publish the three-dimensional structure of the B cell antigen receptor, shedding new light on its composition.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-structure-one-most-important-receptors-immune-system-unraveled
  • Dossier - 01/04/2013 19423_de.jpg

    Retroviruses from infectious agent to therapeutic assistant

    Viruses are infectious particles that use the machinery and metabolism of a host cell to replicate. The family of retroviruses is particularly known for its most notorious representative i. e. the human immunodeficiency virus HIV. However retroviruses are not only of interest for researchers looking for effective cures for viral infections their characteristic properties also make them promising laboratory and gene therapy tools.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/retroviruses-from-infectious-agent-to-therapeutic-assistant
  • Phytopharmaceuticals - 14/09/2020 Cannabisnet_Bild_11.jpg

    Medicinal cannabis to be grown in Germany

    Anyone who thinks hemp is just an inconspicuous plant, whose ingredients can be used, at best, as an intoxicant, can quickly be proven wrong. Besides being used as a valuable raw material for textiles and building materials, the plant has great potential as a medicinal drug. The CANNABIS-NET network, coordinated by the University of Hohenheim, has been set up to establish the basis for producing medicinal hemp in Germany.

    https://www.gesundheitsindustrie-bw.de/en/article/news/medicinal-cannabis-be-grown-germany
  • Press release - 11/01/2021

    CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection

    CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating the induction of robust antibody and T cell responses of its COVID-19 vaccine candidate, CVnCoV, in non-human primates.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevacs-covid-19-vaccine-candidate-cvncov-demonstrated-efficient-protection-non-human-primates-during-sars-cov-2-challenge-infe
  • Article - 11/06/2019 A portrait by Harald Zur Hausen

    New pathogens in beef and cow's milk contributing to the risk of cancer

    A team of researchers led by Nobel laureate Prof. Dr. med. Dr. h.c. mult. Harald zur Hausen has discovered a new type of infectious agent in dairy and meat products produced from European cattle that increases the risk for colon and breast cancer. These so-called Bovine Meat and Milk Factors (BMMFs) are small DNA molecules that are similar in sequence to both bacterial plasmids and certain viruses.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-pathogens-in-beef-and-cows-milk-contributing-to-the-risk-of-cancer
  • Viral cancer therapy - 26/10/2022 Microscopic image of plaque formation by HSV1 viruses (green fluorescing).

    Therapeutic viruses against tumours and metastases

    Viruses can overcome cell barriers and transfer information to their host cells. They know how to make their host cell’s infrastructure work for them. This makes them excellent biotechnological tools, which a research group from the Fraunhofer IGB in Stuttgart is using to its advantage. The team is developing a therapeutic virus that not only recognises and fights tumours, but also has the potential to reach metastases.

    https://www.gesundheitsindustrie-bw.de/en/article/news/therapeutic-viruses-against-tumours-and-metastases
  • Vaccine development - 25/05/2021 AdobeStock_385688184_CROCOTHERY.jpg

    Vaccines - a beacon of hope in the fight against pandemics

    Having long been considered less lucrative for the big pharmaceutical companies, vaccine development is taking off in an unforeseen way in the wake of the COVID-19 pandemic. Financial support is flooding in and all kinds of vaccine development strategies are being deployed. Among the winners in the competition for effective coronavirus vaccines are vaccines based on RNA technology.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/vaccines-beacon-hope-fight-against-pandemics
  • Press release - 14/04/2021

    Engineering T cells for cancer therapy efficiently and safely

    Genetically enhancing a patient's immune cells by adding therapeutic genes to them outside the body is regarded as a promising new treatment approach in oncology. However, the production of these therapeutic cells using viruses is not only expensive but time-consuming. Researchers at the German Cancer Research Center (DKFZ) have developed an innovative non-viral vector that can efficiently introduce therapeutic genes into immune cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/engineering-t-cells-cancer-therapy-efficiently-and-safely
  • Press release - 23/11/2021

    Multi-peptide vaccine against SARS-CoV-2 shows strong T-cell immune response

    At the University Hospital Tübingen, clinical evaluation of an in-house developed vaccine (CoVac-1) against SARS-CoV-2 was started in November 2020 under the direction of Prof. Dr. Juliane Walz in the CCU Translational Immunology of the Medical Clinic (Medical Director Prof. Dr. Helmut Salih). Now the results of the Phase I study are available and demonstrate a potent activation of the T-cell response against the coronavirus.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/multi-peptide-vaccine-against-sars-cov-2-shows-strong-t-cell-immune-response
  • Press release - 24/11/2022

    SARS-CoV-2 detection in 30 minutes using gene scissors

    Researchers of the University of Freiburg introduce biosensor for the nucleic acid amplification-free detection of SARS-CoV-2 RNA.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/sars-cov-2-nachweis-30-minuten-mit-der-genschere
  • Press release - 19/12/2024

    Antibody that neutralizes inhibitory factors involved in nerve regeneration leads to enhanced motor function after acute spinal cord injury

    Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December 2024.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/antibody-neutralizes-inhibitory-factors-involved-nerve-regeneration-leads-enhanced-motor-function-after-acute-spinal-cord-injury
  • Press release - 04/03/2021

    CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV

    CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Novartis AG announced today that they have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV. Preparations for the start of production, technology transfers and test runs are already underway.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-novartis-sign-initial-agreement-manufacturing-covid-19-vaccine-candidate-cvncov
  • Press release - 04/12/2024

    Joint research in key technologies: NMI and KIT sign cooperation agreement

    The NMI Natural and Medical Sciences Institute and the Karlsruhe Institute of Technology (KIT) have signed a groundbreaking cooperation agreement. This partnership combines the expertise of both institutions in the fields of production and characterization of materials for biological systems and energy storage as well as the application of statistical methods in medicine.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/joint-research-key-technologies-nmi-and-kit-sign-cooperation-agreement

Page 5 / 8

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://www.gesundheitsindustrie-bw.de/en/search